Related references
Note: Only part of the references are listed.Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFβR therapy
Sabine Classen et al.
PHARMACOGENETICS AND GENOMICS (2010)
Liver X receptor modulators: Effects on lipid metabolism and potential use in the treatment of atherosclerosis
C. Fievet et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Systems biology approaches and pathway tools for investigating cardiovascular disease
Craig E. Wheelock et al.
MOLECULAR BIOSYSTEMS (2009)
Tolerability and Effects on Lipids of Ezetimibe Coadministered with Pravastatin or Simvastatin for Twelve Months: Results from Two Open-Label Extension Studies in Hypercholesterolemic Patients
John Strony et al.
CLINICAL THERAPEUTICS (2008)
Improvement of inflammatory responses associated with NF-κB pathway in kidneys from diabetic rats
L. Chen et al.
INFLAMMATION RESEARCH (2008)
Off-Target Effects of Psychoactive Drugs Revealed by Genome-Wide Assays in Yeast
Elke Ericson et al.
PLOS GENETICS (2008)
Mouse models for atherosclerosis and pharmaceutical modifiers
Susanne Zadelaar et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Effect of T0901317 on hepatic proinflammatory gene expression in apoE-/- mice fed a high-fat/high-cholesterol diet
Xiaoyan Dai et al.
INFLAMMATION (2007)
Fenofibrate represses interleukin-17 and interferon-γ expression and improves colitis in interleukin-10-deficient mice
Jimmy W. Lee et al.
GASTROENTEROLOGY (2007)
Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism
Yu Xue et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Relating protein pharmacology by ligand chemistry
Michael J. Keiser et al.
NATURE BIOTECHNOLOGY (2007)
Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis
Robert Kleemann et al.
GENOME BIOLOGY (2007)
Fenofibrate reduces atherogenesis in ApoE*3Leiden mice - Evidence for multiple antiatherogenic effects besides lowering plasma cholesterol
T. Kooistra et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-α activators -: Clinical and experimental evidence
A Zambon et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia
B Karten et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Hepatic peroxisomal fatty acid β-oxidation is regulated by liver X receptor α
TH Hu et al.
ENDOCRINOLOGY (2005)
Monocyte release of tumor necrosis factor-α and interleukin-1β in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates
B Okopien et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-α activator fenofibrate
P Gervois et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Drug repositioning: Identifying and developing new uses for existing drugs
TT Ashburn et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Rosuvastatin reduces caspase-3 activity and up-regulates α-secretase in human neuroblastoma SH-SY5Y cells exposed to Aβ
D Famer et al.
NEUROSCIENCE LETTERS (2004)
Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro
R Kleemann et al.
BLOOD (2004)
Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice - Evidence for antiinflammatory effects of rosuvastatin
R Kleemann et al.
CIRCULATION (2003)
Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins
C Gouédard et al.
MOLECULAR PHARMACOLOGY (2003)
Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages
A Castrillo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Drug therapy: Selective estrogen-receptor modulators - Mechanisms of action and application to clinical practice
BL Riggs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation
R Kleemann et al.
BLOOD (2003)
Inflammation and atherosclerosis
P Libby et al.
CIRCULATION (2002)
Global burden of cardiovascular diseases - Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization
S Yusuf et al.
CIRCULATION (2001)
Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β
P Gervois et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
